Etamsilat-Escom 125mg/ml 2ml 10 pcs.

Anthemorrhagic agent.

Normalizes the permeability of the vascular wall, improves microcirculation. The action is apparently due to the activating effect on the formation of thromboplastin.

It does not affect prothrombin time, has no hypercoagulative properties and does not promote the formation of blood clots.

The onset of action is 5-15 min after the intravenous injection, the maximum effect is 1-2 h after injection. The duration of action is 4-6 hours.

Indications

Prevention and treatment of capillary bleeding in diabetic angiopathy, during surgical interventions in otolaryngological practice, ophthalmology, dentistry, urology, surgery and gynecology; emergency cases with intestinal and pulmonary bleeding, with hemorrhagic diathesis.

Pharmacological effect

Antihemorrhagic agent.

Normalizes the permeability of the vascular wall, improves microcirculation. The action is apparently associated with an activating effect on the formation of thromboplastin.

Does not affect prothrombin time, does not have hypercoagulable properties and does not contribute to the formation of blood clots.

The onset of action is 5-15 minutes after intravenous injection, the maximum effect is 1-2 hours after administration. Duration of action – 4-6 hours.

Active ingredient

Etamzilat

Composition

1 ml ethamsylate 125 mg

Excipients:

sodium disulfite 2.5 mg,

sodium sulfite anhydrous 1 mg,

sodium edetate dihydrate 0.5 mg,

water for up to 1 ml.

Contraindications

Thrombosis, thromboembolism, hypersensitivity to etamsylate.

Etamsylate should not be used as the only remedy if the patient has hemorrhages caused by anticoagulants.

Side Effects

Possible heartburn, a feeling of heaviness in the epigastric region, headache, dizziness, facial flushing, decreased systolic blood pressure, paresthesia of the lower extremities.

Interaction

Pharmaceutically incompatible with other drugs.

Manufacturer

Eskom NPK, Russia